|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Hepatocellular carcinoma: recent advances and emerging medical therapies [version 1; peer review: 2 approved]
Kwan-Lung Ko
https://orcid.org/0000-0003-3302-639X
1, Lung-Yi Mak1, Ka-Shing Cheung1, Man-Fung Yuen1,2
Author details
1 Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
2 State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong
Kwan-Lung Ko
Roles: Writing – Original Draft Preparation, Writing – Review & Editing
Lung-Yi Mak
Roles: Writing – Original Draft Preparation, Writing – Review & Editing
Ka-Shing Cheung
Roles: Writing – Original Draft Preparation, Writing – Review & Editing
Man-Fung Yuen
Roles: Conceptualization, Project Administration, Supervision, Writing – Review & Editing
Abstract
Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed.
Keywords
hepatocellular carcinoma, medical therapy
|
|
发表于 2020-6-22 16:07